IPDGC member login ​click here ->

IPDGC exome browser click here ->

IPDGC exome browser click here ->

IPDGC member login click here ->


LOGIN
LOGIN
LOGIN
LOGIN

IPDGC consortium members 

United States of America:
Laboratory of Neurogenetics, National Institute on Aging, Bethesda, MD, USA
Andrew B Singleton 
Aude Nicolas 
J Raphael Gibbs 
Dena G Hernandez 
Xylena Reed 
Mark R Cookson 
Faraz Faghri

Sara Bandrés-Ciga
Hampton L. Leonard

Laboratory of Neurogenetics, National Institute on Aging, Bethesda, USA; Data Tecnica International, Glen Echo, MD, USA
Mike A. Nalls

Baylor College of Medicine, Houston, Texas, USA 
Joshua M. Shulman 
Laurie Robak

National Institutes of Health Parkinson Clinic, NINDS, National Institutes of Health, Bethesda, MD, USA
Codrin Lungu

Department of Translational Genomics, Keck School of Medicine, University of Southern California, Los Angeles, USA
David W. Craig

Neurogenomics Division, TGen, Phoenix, AZ USA
Kendall Van Keuren-Jensen

Neurodegenerative Diseases Research Unit, National Institute of Neurological Disorders and Stroke, Bethesda, MD, USA
Sonja Scholz
Cornelis Blauwendraat 

Departments of Neurology and Physiology, University of California, San Francisco
Steven Finkbeiner 

Northwestern University Feinberg School of Medicine, Chicago, IL, USA
Steven Lubbe
Niccolo E. Mencacci

Department of Neurology, College of Physicians and Surgeons, Columbia University Medical Center, New York, NY, USA
Roy N. Alcalay

United Kingdom:
Department of Molecular Neuroscience, UCL Institute of Neurology, London, UK
Helene Plun-Favreau 
John Hardy 
Jose M Bras 
Kin Y Mok
Lea R’Bibo
Mina Ryten

Mie Rizig
Rita Guerreiro
Alastair J Noyce
Sebastian Guelfi
Rauan Kaiyrzhanov

Neurogenetics lab, Department of Molecular Neuroscience, UCL Institute of Neurology, London, UK.
Viorica Chelban
Henry Houlden

Biostatistics & Bioinformatics Unit, Institute of Psychological Medicine and Clinical Neuroscience, MRC Centre for Neuropsychiatric Genetics & Genomics, Cardiff, UK
Peter Holmans

Institute of Translational Medicine, University of Liverpool, Liverpool, UK
John Quinn
Kimberley Billingsley
Ben Middlehurst

MRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff University School of Medicine, Cardiff, UK
Valentina Escott-Price
Nigel Williams

Department of Clinical Neuroscience, University College London, London, UK
Huw R Morris
Manuela Tan

UCL Genetics Institute; and Department of Molecular Neuroscience, UCL Institute of Neurology, London, UK
Demis Kia
Nicholas W Wood
Thomas Foltynie
Sebastian Schreglmann

University College London, London, UK
Ruth Lovering

University of Reading, Reading, UK
Patrick Lewis
Claudia Manzoni

Germany:
Department for Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research, University of Tübingen, and DZNE, German Center for Neurodegenerative Diseases, Tübingen, Germany
Peter Heutink
Thomas Gasser
Javier Simón-Sánchez
Patrizia Rizzu 
Manu Sharma
Claudia Schulte
Kathrin Brockmann


France:
Institut du Cerveau et de la Moelle épinière, ICM, Inserm U 1127, CNRS, UMR 7225, Sorbonne Universités, UPMC University Paris 06, UMR S 1127, AP-HP, Pitié-Salpêtrière Hospital, Paris, France
Alexis Brice
Fabrice Danjou
Suzanne Lesage
Jean-Christophe Corvol


INSERM UMR 1220; and Paul Sabatier University, Toulouse, France
Maria Martinez


Canada:
Montreal Neurological Institute and Hospital, Department of Neurology & Neurosurgery, Department of Human Genetics, McGill University, Montréal, QC, H3A 0G4, Canada
Guy A. Rouleau
Ziv Gan-Or
Lynne Krohn

Estonia:
Department of Neurology and Neurosurgery, University of Tartu, Tartu, Estonia
Pille Taba

Department of Pathophysiology, University of Tartu, Tartu, Estonia
Sulev Koks

The Netherlands:
Department of Neurology, Leiden University Medical Center, Leiden, Netherlands.
Jacobus J van Hilten
Johan Marinus
 
Norway:
Department of Neurology, Oslo University Hospital, Oslo, Norway
Lasse Pihlstrom

Austria:
Department of Neurology, Medizinische Universität Wien, Austria
Alexander Zimprich


Spain:
Universidad de Murcia, Murcia, Spain
Juan A. Botía

Israel:
The Movement Disorders Institute, Department of Neurology and Sagol Neuroscience Center, Chaim Sheba Medical Center, Tel-Hashomer, Ramat Gan, Israel, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
Sharon Hassin-Baer

IPDGC ACKNOWLEDGMENTS

We would like to thank all of the subjects who donated their time and biological samples to be a part of this study. We also would like to thank all members of the International Parkinson Disease Genomics Consortium (IPDGC). See for a complete overview of members, acknowledgements and funding http://pdgenetics.org/partners.This work was supported in part by the Intramural Research Programs of the National Institute of Neurological Disorders and Stroke (NINDS), the National Institute on Aging (NIA), and the National Institute of Environmental Health Sciences both part of the National Institutes of Health, Department of Health and Human Services; project numbers 1ZIA-NS003154, Z01-AG000949-02 and Z01-ES101986. In addition this work was supported by the Department of Defense (award W81XWH-09-2-0128), and The Michael J Fox Foundation for Parkinson’s Research. This work was supported by National Institutes of Health grants R01NS037167, R01CA141668, P50NS071674, American Parkinson Disease Association (APDA); Barnes Jewish Hospital Foundation; Greater St Louis Chapter of the APDA. The KORA (Cooperative Research in the Region of Augsburg) research platform was started and financed by the Forschungszentrum für Umwelt und Gesundheit, which is funded by the German Federal Ministry of Education, Science, Research, and Technology and by the State of Bavaria. This study was also funded by the German Federal Ministry of Education and Research (BMBF) under the funding code 031A430A, the EU Joint Programme - Neurodegenerative Diseases Research (JPND) project under the aegis of JPND -www.jpnd.eu- through Germany, BMBF, funding code 01ED1406 and iMed - the Helmholtz Initiative on Personalized Medicine. This study is funded by the German National Foundation grant (DFG SH599/6-1) (grant to M.S), Michael J Fox Foundation, and MSA Coalition, USA (to M.S). The French GWAS work was supported by the French National Agency of Research (ANR-08-MNP-012). This study was also funded by France-Parkinson Association, Fondation de France, the French program “Investissements d’avenir” funding (ANR-10-IAIHU-06) and a grant from Assistance Publique-Hôpitaux de Paris (PHRC, AOR-08010) for the French clinical data. This study was also sponsored by the Landspitali University Hospital Research Fund (grant to SSv); Icelandic Research Council (grant to SSv); and European Community Framework Programme 7, People Programme, and IAPP on novel genetic and phenotypic markers of Parkinson’s disease and Essential Tremor (MarkMD), contract number PIAP-GA-2008-230596 MarkMD (to HP and JHu). Institutional research funding IUT20-46 was received of the Estonian Ministry of Education and Research (SK). The McGill study was funded by the Michael J. Fox Foundation and the Canadian Consortium on Neurodegeneration in Aging (CCNA). This study utilized the high-performance computational capabilities of the Biowulf Linux cluster at the National Institutes of Health, Bethesda, Md. (http://biowulf.nih.gov), and DNA panels, samples, and clinical data from the National Institute of Neurological Disorders and Stroke Human Genetics Resource Center DNA and Cell Line Repository. People who contributed samples are acknowledged in descriptions of every panel on the repository website. We thank the French Parkinson’s Disease Genetics Study Group and the Drug Interaction with genes (DIGPD) study group: Y Agid, M Anheim, F Artaud, A-M Bonnet, C Bonnet, F Bourdain, J-P Brandel, C Brefel-Courbon, M Borg, A Brice, E Broussolle, F Cormier-Dequaire, J-C Corvol, P Damier, B Debilly, B Degos, P Derkinderen, A Destée, A Dürr, F Durif, A Elbaz, D Grabli, A Hartmann, S Klebe, P. Krack, J Kraemmer, S Leder, S Lesage, R Levy, E Lohmann, L Lacomblez, G Mangone, L-L Mariani, A-R Marques, M Martinez, V Mesnage, J Muellner, F Ory-Magne, F Pico, V Planté-Bordeneuve, P Pollak, O Rascol, K Tahiri, F Tison, C Tranchant, E Roze, M Tir, M Vérin, F Viallet, M Vidailhet, A You. We also thank the members of the French 3C Consortium: A Alpérovitch, C Berr, C Tzourio, and P Amouyel for allowing us to use part of the 3C cohort, and D Zelenika for support in generating the genome-wide molecular data. We thank P Tienari (Molecular Neurology Programme, Biomedicum, University of Helsinki), T Peuralinna (Department of Neurology, Helsinki University Central Hospital), L Myllykangas (Folkhalsan Institute of Genetics and Department of Pathology, University of Helsinki), and R Sulkava (Department of Public Health and General Practice Division of Geriatrics, University of Eastern Finland) for the Finnish controls (Vantaa85+ GWAS data). We used genome-wide association data generated by the Wellcome Trust Case-Control Consortium 2 (WTCCC2) from UK patients with Parkinson’s disease and UK control individuals from the 1958 Birth Cohort and National Blood Service. Genotyping of UK replication cases on ImmunoChip was part of the WTCCC2 project, which was funded by the Wellcome Trust (083948/Z/07/Z). UK population control data was made available through WTCCC1. This study was supported by the Medical Research Council and Wellcome Trust disease centre (grant WT089698/Z/09/Z to NW, JHa, and ASc). As with previous IPDGC efforts, this study makes use of data generated by the Wellcome Trust Case-Control Consortium. A full list of the investigators who contributed to the generation of the data is available from www.wtccc.org.uk. Funding for the project was provided by the Wellcome Trust under award 076113, 085475 and 090355. This study was also supported by Parkinson’s UK (grants 8047 and J-0804) and the Medical Research Council (G0700943 and G1100643). Sequencing and genotyping done in McGill University was supported by grants from the Michael J. Fox Foundation, the Canadian Consortium on Neurodegeneration in Aging (CCNA) and in part thanks to funding from the Canada First Research Excellence Fund (CFREF), awarded to McGill University for the Healthy Brains for Healthy Lives (HBHL) program. We thank Jeffrey Barrett and Jason Downing (Illumina Inc) for assistance with the design of the ImmunoChip and NeuroX arrays. DNA extraction work that was done in the UK was undertaken at University College London Hospitals, University College London, who received a proportion of funding from the Department of Health’s National Institute for Health Research Biomedical Research Centres funding. This study was supported in part by the Wellcome Trust/Medical Research Council Joint Call in Neurodegeneration award (WT089698) to the Parkinson’s Disease Consortium (UKPDC), whose members are from the UCL Institute of Neurology, University of Sheffield, and the Medical Research Council Protein Phosphorylation Unit at the University of Dundee. We thank the Quebec Parkinson’s Network (http://rpq-qpn.org) and its members. This work was supported by the Medical Research Council grant MR/N026004/1. The Braineac project was supported by the MRC through the MRC Sudden Death Brain Bank Grant (MR/G0901254) to J.H. P.A.L. was supported by the MRC (grants MR/N026004/1 and MR/L010933/1) and Michael J. Fox Foundation for Parkinson’s Research. Mike A. Nalls’ participation is supported by a consulting contract between Data Tecnica International and the National Institute on Aging, NIH, Bethesda, MD, USA, as a possible conflict of interest Dr. Nalls also consults for Illumina Inc, Lysosomal Therapeutics Inc, the Michael J. Fox Foundation and Vivid Genomics among others.